GlassScriptPhysician profile
Anthony A Flood
NPI 1083879035
$1,175.51
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $314 · 2020: $131 · 2021: $295 · 2022: $110 · 2023: $226 · 2024: $99.14.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $326.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $325.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $256.16 | 2019-2021 | |
| Mayne Pharma Commercial LLC | $186.64 | 2020-2023 | |
| Arcutis Biotherapeutics, INC. | $157.78 | 2023-2024 | Zoryve |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $131.72 | 2019 | |
| Abbvie INC. | $91.36 | 2020-2021 | |
| Sun Pharmaceutical Industries INC. | $76.83 | 2021-2023 | Absorica Ld, Winlevi |
| Mission Pharmacal Company | $72.34 | 2019-2020 | |
| Galderma Laboratories, L.P. | $47.58 | 2019-2020 | |
| Strata Skin Sciences, INC. | $38.86 | 2023 | Xtrac |
| Amgen INC. | $34.78 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.37 | 2024 | Spevigo |
| Leo Pharma INC. | $31.29 | 2021 | |
| Paratek Pharmaceuticals, INC. | $18.80 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Flood listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.